Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Sponsor: Neurocrine Biosciences
Summary
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-01-22
Completion Date
2027-07
Last Updated
2025-10-29
Healthy Volunteers
No
Conditions
Interventions
NBI-1065845
NBI-1065845 tablets
Placebo
Matching placebo tablets
Locations (18)
Neurocrine Clinical Site
Little Rock, Arkansas, United States
Neurocrine Clinical Site
Garden Grove, California, United States
Neurocrine Clinical Site
Orange, California, United States
Neurocrine Clinical Site
Pico Rivera, California, United States
Neurocrine Clinical Site
San Diego, California, United States
Neurocrine Clinical Site
Upland, California, United States
Neurocrine Clinical Site
Hollywood, Florida, United States
Neurocrine Clinical Site
Maitland, Florida, United States
Neurocrine Clinical Site
Boston, Massachusetts, United States
Neurocrine Clinical Site
Watertown, Massachusetts, United States
Neurocrine Clinical Site
Mount Kisco, New York, United States
Neurocrine Clinical Site
Avon Lake, Ohio, United States
Neurocrine Clinical Site
Westlake, Ohio, United States
Neurocrine Clinical Site
Dallas, Texas, United States
Neurocrine Clinical Site
Houston, Texas, United States
Neurocrine Clinical Site
Richmond, Texas, United States
Neurocrine Clinical Site
The Woodlands, Texas, United States
Neurocrine Clinical Site
Everett, Washington, United States